GO:0035442 dipeptide transmembrane transport: Transport Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035442 (dipeptide transmembrane transport) describes the directed movement of a dipeptide across a membrane by a transporter or pore [1,2].
• The process is mediated by membrane proteins such as SLC15A1 (PEPT1) and SLC15A2 (PEPT2), which use proton gradients to transport dipeptides [2,3].
• Dipeptide transporters are important for nutrient absorption, drug delivery, and cellular signaling [3,7].
• Experimental models include Caco-2 monolayers, brush-border membrane vesicles, and CRISPR-engineered cell lines [3,6].
• Dysregulation of dipeptide transport is linked to cancer, metabolic disorders, and drug resistance.
• Research methods include transport assays, electrophysiology, and CRISPR screening to identify novel transporters [2,8].
Description
Dipeptide transmembrane transport (GO:0035442) is the biological process by which dipeptides, composed of two amino acids linked by a peptide bond, are moved across cellular membranes by dedicated transporters or pores [1,2]. This process is essential for the absorption of dietary protein breakdown products and for the cellular uptake of peptide-based drugs [3,7]. The major transporters responsible belong to the solute carrier family, notably SLC15A1 (PEPT1) and SLC15A2 (PEPT2), which couple dipeptide transport to proton gradients [2,3]. Understanding this process is critical for nutrition, pharmacology, and cancer research, as dipeptide transporters can influence drug bioavailability and tumor metabolism [7,8]. Recent studies have also explored artificial dipeptide transporters for therapeutic applications.
dipeptide transmembrane transport At A Glance
| GO ID | GO:0035442 |
|---|---|
| GO term | dipeptide transmembrane transport |
| Ontology | biological_process |
| Synonym | dipeptide membrane transport |
| Major function | Transport of dipeptides across cellular membranes |
| Cellular location | Plasma membrane, brush-border membrane |
| Key transporters | SLC15A1 (PEPT1), SLC15A2 (PEPT2) |
| Energy coupling | Proton gradient (H+ symport) |
| Related diseases | Cancer, metabolic disorders, drug resistance |
What Is GO:0035442?
GO:0035442 is defined as the directed movement of a dipeptide across a membrane by means of some agent such as a transporter or pore. A dipeptide is a combination of two amino acids linked together by a peptide (-CO-NH-) bond. This process requires a transmembrane transporter protein and typically occurs against a concentration gradient, often driven by proton or ion gradients [1,2].
Why Is dipeptide transmembrane transport Important in Cell Biology?
Dipeptide transmembrane transport is fundamental for nutrient uptake and drug absorption, and its dysregulation is implicated in various diseases. Transporters like PEPT1 are targets for improving oral drug delivery, while their overexpression in cancer cells supports tumor growth by supplying amino acids [7,8]. Studying this process aids in understanding membrane transport mechanisms and developing therapeutic strategies [3,8].
• Enables absorption of dietary dipeptides in the intestine and kidney.
• Facilitates cellular uptake of peptide-based drugs, impacting pharmacokinetics.
• Plays a role in cancer metabolism by supplying amino acids to tumor cells.
• Involved in neuropeptide transport and signaling.
• Provides a model for studying membrane transporter structure-function.
• Potential target for artificial transporters in synergistic cancer therapy.
• Contributes to drug-drug interactions at the transporter level.
• Essential for maintaining amino acid homeostasis in crustaceans and other organisms.
What Happens During dipeptide transmembrane transport?
Substrate recognition and binding
In simple terms: The transporter recognizes and binds a dipeptide on one side of the membrane.
Dipeptide transporters such as PEPT1 and PEPT2 possess a binding pocket that accommodates dipeptides with varying side chains. Cysteine scanning of transmembrane domain three of the human dipeptide transporter revealed critical residues for substrate transport. The binding is stereospecific and requires the peptide bond.
Proton-coupled translocation
In simple terms: The transporter uses a proton gradient to move the dipeptide across the membrane.
Transport is driven by the inward-directed proton gradient. The transporter undergoes conformational changes to translocate the dipeptide and proton together. This mechanism is shared with other solute carriers and is essential for active transport against concentration gradients.
Release and recycling
In simple terms: The dipeptide is released inside the cell, and the transporter resets for another cycle.
After release into the cytoplasm, the transporter returns to its original conformation. Dipeptides can then be hydrolyzed by intracellular peptidases, such as aminopeptidase N, which interacts with transported dipeptides. This ensures a continuous supply of amino acids.
Regulation by cellular signals
In simple terms: Cells can adjust how many transporters are active based on need.
The expression and activity of dipeptide transporters are regulated by nutritional status, hormones, and stress. For example, insulin and leptin can modulate PEPT1 activity. This regulation ensures efficient nutrient uptake under varying conditions.
Key Genes Involved in GO:0035442 dipeptide transmembrane transport
The following genes encode proteins directly involved in dipeptide transmembrane transport or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC15A1 | Intestinal dipeptide transporter (PEPT1) | Drug absorption, nutrient uptake [3,7] |
| SLC15A2 | Kidney and brain dipeptide transporter (PEPT2) | Neurotransmitter transport, drug clearance |
| SLC15A3 | Endosomal/lysosomal dipeptide transporter | Immune response, antigen presentation |
| SLC15A4 | Endolysosomal histidine and dipeptide transporter | Autoimmune diseases, TLR signaling |
| ANPEP | Aminopeptidase N, interacts with transported dipeptides | Cancer, peptide hydrolysis |
| ACE2 | Angiotensin-converting enzyme 2, amino acid transporter | COVID-19, cardiovascular |
| SLC7A1 | Cationic amino acid transporter | Amino acid homeostasis |
| SLC3A2 | Heavy chain of amino acid transporters | Cancer metabolism |
| SLC7A5 | L-type amino acid transporter | mTOR signaling, cancer |
| SLC38A2 | Sodium-coupled neutral amino acid transporter | Nutrient sensing |
| SLC6A19 | Neutral amino acid transporter | Hartnup disorder |
| SLC36A1 | Proton-coupled amino acid transporter | Drug transport |
| SLC16A10 | Aromatic amino acid transporter | Thyroid hormone transport |
| SLC43A1 | L-type amino acid transporter | Cancer cell growth |
| SLC43A2 | L-type amino acid transporter | T cell function |
| SLC1A5 | Neutral amino acid transporter | Glutamine metabolism |
| SLC7A11 | Cystine/glutamate antiporter | Ferroptosis, cancer |
How Is dipeptide transmembrane transport Regulated?
Dipeptide transmembrane transport is regulated at multiple levels. Transcriptional regulation of SLC15A1 and SLC15A2 occurs in response to dietary protein, hormones, and circadian rhythms. Post-translational modifications, such as phosphorylation, can alter transporter activity. Additionally, the proton gradient that drives transport is maintained by Na+/H+ exchangers and other ion pumps. In cancer cells, oncogenic signaling pathways like mTOR can upregulate amino acid transporters to support growth.
dipeptide transmembrane transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC15A1 | Cancer, drug absorption | Caco-2 knockout cells |
| SLC15A2 | Neurodegeneration, pain | Knockout mice, neuronal cultures |
| SLC15A4 | Autoimmune diseases | Knockout macrophages |
| ANPEP | Cancer, peptide hydrolysis | Overexpression in cancer cell lines |
| SLC7A11 | Ferroptosis, cancer | CRISPR knockout in tumor models |
Cancer
Dipeptide transporters are often overexpressed in cancer cells to meet increased demand for amino acids. For example, SLC15A1 and SLC15A2 can supply dipeptides that fuel tumor growth. Targeting these transporters with artificial systems has shown promise in synergistic cancer therapy.
Metabolic disorders
Mutations in amino acid transporters, including dipeptide transporters, can cause metabolic disorders such as Hartnup disease and cystinuria. These conditions highlight the importance of transport in maintaining amino acid homeostasis.
Neurological disorders
PEPT2 (SLC15A2) is expressed in the brain and transports neuropeptides. Its dysfunction has been implicated in neurodegenerative diseases and pain signaling. Modulators of related channels are being explored for chronic pain.
From dipeptide transmembrane transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLC15A1 mediate dipeptide uptake? | SLC15A1 knockout Caco-2 cells |
| What is the role of SLC15A2 in brain? | SLC15A2 knockout mice |
| Can artificial transporters enhance drug delivery? | Knock-in of artificial transporter in cancer cells |
| How does a point mutation affect transport? | Point mutation knock-in of SLC15A1 |
| Is SLC15A4 required for immune signaling? | SLC15A4 knockout macrophages |
| Does overexpression of PEPT1 increase drug sensitivity? | Overexpression of SLC15A1 in HEK293 cells |
How to Study the dipeptide transmembrane transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand uptake | Transport rate and affinity | Kinetic analysis |
| Patch-clamp | Transporter currents | Electrogenic transport |
| CRISPR screen | Gene essentiality | Discovery of novel transporters |
| RNA-seq | Transporter expression | Regulation studies |
| Proteomics | Protein abundance | Membrane protein quantification |
| Fluorescence microscopy | Subcellular localization | Trafficking studies |
| Caco-2 monolayer | Intestinal permeability | Drug absorption prediction |
| Membrane vesicles | Brush-border transport | Tissue-specific transport |
Transport assays
Radiolabeled or fluorescent dipeptides are used to measure uptake in cells or membrane vesicles. This method quantifies transport kinetics and substrate specificity [3,6].
Electrophysiology
Patch-clamp and two-electrode voltage clamp can measure transporter currents coupled to proton movement, providing real-time activity data.
CRISPR screening
Genome-wide CRISPR knockout screens can identify genes essential for dipeptide transport, revealing novel transporters and regulators.
Proteomics and imaging
Mass spectrometry and fluorescence microscopy localize transporters and quantify expression changes under different conditions.
How CRISPR Can Be Used to Study GO:0035442 dipeptide transmembrane transport
Knockout
CRISPR knockout of SLC15A1 or SLC15A2 in cell lines such as Caco-2 or HEK293 abolishes dipeptide transport, allowing researchers to confirm the role of these transporters in uptake and drug sensitivity [3,7].
Point Mutation
Introducing point mutations in transporter genes can mimic human polymorphisms or disrupt key residues, revealing structure-function relationships and transport mechanisms.
Knock-in
Knock-in of tagged transporters (e.g., GFP) enables live-cell imaging and proteomic analysis of transporter localization and interactions.
Overexpression
Overexpression of SLC15A1 or artificial transporters in cancer cells can enhance dipeptide uptake and increase sensitivity to peptide-based drugs, providing a model for synergistic therapy.
How EDITGENE Supports dipeptide transmembrane transport Research
Researchers studying dipeptide transmembrane transport-related genes often need to determine whether a candidate gene is causally involved in transport, drug response, or disease. EDITGENE provides comprehensive CRISPR services to create precise cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for dipeptide transmembrane transport research.
Frequently Asked Questions About dipeptide transmembrane transport
What is dipeptide transmembrane transport?
It is the process of moving a dipeptide across a membrane by a transporter or pore, as defined by GO:0035442 [1,2].
What genes are involved in dipeptide transmembrane transport?
Key genes include SLC15A1, SLC15A2, SLC15A3, and SLC15A4, which encode proton-coupled dipeptide transporters [2,3,5].
How is dipeptide transport regulated?
It is regulated by proton gradients, hormones, and transcriptional changes in response to diet and stress.
What diseases are linked to dipeptide transport?
Cancer, metabolic disorders, and neurological conditions have been associated with altered dipeptide transport [1,7,8].
What methods study dipeptide transport?
Common methods include radioligand uptake assays, patch-clamp, CRISPR screens, and Caco-2 monolayers [2,3,6,8].
Can CRISPR be used to study dipeptide transporters?
Yes, CRISPR knockout, knock-in, and point mutation models are powerful tools to dissect transporter function [2,3,8].
What is the role of PEPT1 in drug absorption?
PEPT1 (SLC15A1) transports dipeptides and peptide-like drugs, influencing oral bioavailability [3,7].
Are there artificial dipeptide transporters?
Yes, artificial transporters have been developed for synergistic cancer therapy.
What is the clinical relevance of dipeptide transport?
It impacts nutrition, drug delivery, and cancer metabolism, making it a target for therapeutic intervention [7,8].
How does dipeptide transport differ from amino acid transport?
Dipeptide transport moves two amino acids linked by a peptide bond, while amino acid transport moves single amino acids, often via different transporters [2,7].
Conclusion
Dipeptide transmembrane transport (GO:0035442) is a vital biological process mediated by proton-coupled transporters such as PEPT1 and PEPT2. It is essential for nutrient absorption, drug delivery, and cellular signaling, with implications in cancer, metabolic, and neurological diseases. Advances in CRISPR technology and transport assays continue to unravel its mechanisms, offering new therapeutic opportunities.
References
- 1. Gomez K et al.. 2023. A peptidomimetic modulator of the Ca(V)2.2 N-type calcium channel for chronic pain.. Proc Natl Acad Sci U S A 120(47):e2305215120 PMID: 37972067
- 2. Links JL et al.. 2007. Cysteine scanning of transmembrane domain three of the human dipeptide transporter: implications for substrate transport.. J Drug Target 15(3):218-25 PMID: 17454359
- 3. Qi H et al.. 2021. Two Dipeptide-Bound Pyrralines with Ile or Ala: A Study on Their Synthesis, Transport across Caco-2 Cell Monolayers, and Interaction with Aminopeptidase N.. J Agric Food Chem 69(37):10962-10973 PMID: 34493043
- 5. Tyler D et al.. 2022. Discovery and Characterization of the Phospholemman/SIMP/Viroporin Superfamily.. Microb Physiol 32(3-4):83-94 PMID: 35152214
- 6. Thamotharan M et al.. 1996. Dipeptide transport by crustacean hepatopancreatic brush-border membrane vesicles.. J Exp Biol 199(Pt 3):635-41 PMID: 9318360
- 7. Liu L et al.. 2006. An integrated approach to model hepatic drug clearance.. Eur J Pharm Sci 29(3-4):215-30 PMID: 16806855
- 8. Luo D et al.. 2025. Artificial Tyroserleutide Transporters for Synergistic Cancer Therapy.. JACS Au 5(6):2580-2592 PMID: 40575313
